Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they say Sunday's new data complement the supporting evidence they’ve already generated.
Private companies have been taking advantage of climbing prices by buying older drugs on the cheap, hiking their stickers, and reselling them, Bloomberg reports, citing data from software company Connecture.
Concordia Healthcare to Buy Some Assets of Covis Pharma for $1.2 Billion